Positive results with Roche's dry-AMD drug candidate
Swiss drug major Roche (ROG: SIX) has announced positive results from the Phase II MAHALO study showing that lampalizumab achieved a 20.4% (p<0.1170) reduction rate in the area of geographic atrophy (GA) at 18 months in patients with an advanced form of dry age-related macular degeneration (AMD).
In a specific sub-population of GA patients treated monthly with lampalizumab who were identified using exploratory biomarkers, the GA progression rate was decreased by 44% (p<0.005) at 18 months.
In the subset of patients positive for the exploratory biomarkers who presented with better vision (20/50 to 20/100), progression of the GA area was reduced by 54% (p<0.005) at 18 months when treated with monthly lampalizumab. About 57% of patients in the MAHALO study showed positive response to the exploratory biomarkers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze